Details of the Drug

General Information of Drug (ID: DMJPBAX)

Drug Name

Oxybutynine

Synonyms

5633-20-5; Ditropan; Oxytrol; Oxibutyninum; Oxybutyninum; Oxibutinina; Oxybutyninum [INN-Latin]; Oxybutynine [INN-French]; Oxybutinin; Cystrin; Oxibutinina [INN-Spanish]; Oxybutynin Base; transdermal patch; Lyrinel XL; Oxybutynin [USAN:INN:BAN]; 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat; CCRIS 1923; oxybutynin topical gel; Ditropan Xl; Oxybutynin (Ditropan); HSDB 3270; 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate; CHEMBL1231; Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-b

Indication

Disease Entry	ICD 11	Status	REF
Obsolete neurogenic bladder	N.A.	Approved	[1]
Discovery agent	N.A.	Investigative	[2]
Priapism	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

357.5

Logarithm of the Partition Coefficient (xlogp)

4.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 45 min-2.25 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 94% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 5.1 mL/min/kg [4]
Elimination: Oxybutynin is heavily cleared by the liver, and less than 0.1% of an administered dose is found as unchanged drug in the urine [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [6]
Metabolism: The drug is metabolized via the CYP3A4 enzyme system in both the liver and the wall of the intestine [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.93148 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.0034% [4]
Vd: The volume of distribution (Vd) of drug is 193 L [9]
Water Solubility: The ability of drug to dissolve in water is measured as 0.8 mg/mL [3]

Chemical Identifiers

Formula: C22H31NO3
IUPAC Name: 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
Canonical SMILES: CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
InChI: InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
InChIKey: XIQVNETUBQGFHX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4634
ChEBI ID: CHEBI:7856
CAS Number: 5633-20-5
DrugBank ID: DB01062
TTD ID: D0F5LH
ACDINA ID: D00501

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M3 (CHRM3)	TTQ13Z5	ACM3_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[10]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[11]
Cocaine esterase (CES2)	OTC647SQ	EST2_HUMAN	Biotransformations	[12]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Gene/Protein Processing	[13]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[10]
Interleukin-24 (IL24)	OT4VUWH1	IL24_HUMAN	Gene/Protein Processing	[10]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Gene/Protein Processing	[14]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Obsolete neurogenic bladder

ICD Disease Classification

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M3 (CHRM3)	DTT	CHRM3	4.61E-07	-0.59	-0.73

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxybutynine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Oxybutynine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Oxybutynine and Oliceridine.	Acute pain [MG31]	[16]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[17]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[17]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[18]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Cariprazine.	Bipolar disorder [6A60]	[18]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Oxybutynine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Oxybutynine when combined with Acetylcholine.	Cataract [9B10]	[20]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[21]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[21]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[21]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Oxybutynine and Dihydrocodeine.	Chronic pain [MG30]	[22]
Arbutamine	DMCY8AF	Moderate	Increased risk of rapid heart rate by the combination of Oxybutynine and Arbutamine.	Coronary atherosclerosis [BA80]	[23]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Oxybutynine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[24]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and OPC-34712.	Depression [6A70-6A7Z]	[18]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Clomipramine.	Depression [6A70-6A7Z]	[18]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Doxepin.	Depression [6A70-6A7Z]	[17]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Mepenzolate.	Digestive system disease [DE2Z]	[18]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Oxybutynine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Oxybutynine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Oxybutynine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[18]
Nadolol	DMW6GVL	Moderate	Antagonize the effect of Oxybutynine when combined with Nadolol.	Essential hypertension [BA00]	[15]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Oxybutynine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[27]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Solifenacin.	Functional bladder disorder [GC50]	[18]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Oxybutynine when combined with Pilocarpine.	Glaucoma [9C61]	[28]
Carvedilol	DMHTEAO	Moderate	Antagonize the effect of Oxybutynine when combined with Carvedilol.	Heart failure [BD10-BD1Z]	[15]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Oxybutynine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[29]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Oxybutynine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[30]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Oxybutynine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[31]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Oxybutynine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Oxybutynine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Acebutolol	DM0TI4U	Moderate	Antagonize the effect of Oxybutynine when combined with Acebutolol.	Hypertension [BA00-BA04]	[15]
Penbutolol	DM4ES8F	Moderate	Antagonize the effect of Oxybutynine when combined with Penbutolol.	Hypertension [BA00-BA04]	[15]
Nebivolol	DM7F1PA	Moderate	Antagonize the effect of Oxybutynine when combined with Nebivolol.	Hypertension [BA00-BA04]	[15]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[18]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Oxybutynine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[34]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and ITI-007.	Insomnia [7A00-7A0Z]	[18]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Oxybutynine when combined with R0-93877.	Irritable bowel syndrome [DD91]	[26]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Oxybutynine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[35]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Oxybutynine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[36]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Oxybutynine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Oxybutynine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[37]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Oxybutynine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[38]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Oxybutynine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Oxybutynine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[39]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Oxybutynine when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[40]
Ambenonium	DMOP0BL	Moderate	Antagonize the effect of Oxybutynine when combined with Ambenonium.	Myasthenia gravis [8C6Y]	[40]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Oxybutynine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Oxybutynine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[41]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Oxybutynine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[42]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Phenindamine.	Nasopharyngitis [CA00]	[18]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Promethazine.	Nausea/vomiting [MD90]	[18]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Cyclizine.	Nausea/vomiting [MD90]	[18]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Oxybutynine when combined with Metoclopramide.	Nausea/vomiting [MD90]	[43]
Polythiazide	DMCH80F	Minor	Altered absorption of Oxybutynine due to GI dynamics variation caused by Polythiazide.	Oedema [MG29]	[44]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Oxybutynine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[22]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Oxybutynine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[45]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Oxybutynine and Oxymorphone.	Pain [MG30-MG3Z]	[16]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Oxybutynine and Dezocine.	Pain [MG30-MG3Z]	[16]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Flavoxate.	Pain [MG30-MG3Z]	[18]
Levodopa	DMN3E57	Moderate	Altered absorption of Oxybutynine due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[46]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Orphenadrine.	Parkinsonism [8A00]	[18]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Oxybutynine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[47]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Methylscopolamine.	Peptic ulcer [DA61]	[18]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Oxybutynine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[48]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Oxybutynine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[49]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Oxybutynine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[50]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[18]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Quetiapine.	Schizophrenia [6A20]	[18]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Aripiprazole.	Schizophrenia [6A20]	[18]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Iloperidone.	Schizophrenia [6A20]	[18]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Paliperidone.	Schizophrenia [6A20]	[18]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Molindone.	Schizophrenia [6A20]	[18]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Thiothixene.	Schizophrenia [6A20]	[18]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Asenapine.	Schizophrenia [6A20]	[18]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Pimozide.	Schizophrenia [6A20]	[18]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Oxybutynine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[51]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Oxybutynine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[15]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Oxybutynine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[52]
Armodafinil	DMGB035	Minor	Increased metabolism of Oxybutynine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[53]
LEE011	DMMX75K	Moderate	Decreased metabolism of Oxybutynine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[54]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Oxybutynine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[15]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Oxybutynine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[55]
Pramlintide	DM0EZ9Q	Moderate	Altered absorption of Oxybutynine due to GI dynamics variation caused by Pramlintide.	Type-1/2 diabete [5A10-5A11]	[56]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[18]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[17]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Oxybutynine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[18]
-----------


⏷ Show the Full List of 88 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acrylic acid	E00132	6581	Other agent
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
D&C red no. 27	E00381	83511	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben	E00149	7456	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Food blue 1 aluminum lake	E00512	11979396	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Dextrose anhydrous	E00394	107526	Binding agent; Diluent; Flavoring agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Water	E00035	962	Solvent
FD&C Green 3	E00682	16887	Colorant
Haematite red	E00236	14833	Colorant
Sorbitan tristearate	E00516	17800859	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Cellulose acetate	E00702	Not Available	Coating agent; Modified-release agent; Diluent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 49 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Oxybutynin 10 mg tablet	10 mg	24 HR Extended Release Oral Tablet	Oral
Oxybutynin 15 mg tablet	15 mg	24 HR Extended Release Oral Tablet	Oral
Oxybutynin 5 mg tablet	5 mg	24 HR Extended Release Oral Tablet	Oral
Oxybutynin 5mg extended release tablet	5mg	Extended Release Tablet	Oral
Oxybutynin 5mg/5ml Syrup	5mg/5ml	Syrup	Oral
Oxybutynin 5 mg tablet	5 mg	Oral Tablet	Oral
Oxybutynin 5mg tablet	5mg	Tablet	Oral
Oxybutynin 3.9mg extended release film	3.9mg	Extended Release Film	Transdermal

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2	Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor. Biochem J. 2008 May 15;412(1):103-12.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A: The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988;35(5):515-20. doi: 10.1007/bf00558247.
6	A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010 Winter;12(1):12-9.
7	Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Ditropan XL FDA label
10	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
11	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
12	Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull. 1997 Aug;20(8):869-73. doi: 10.1248/bpb.20.869.
13	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
14	Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
17	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
18	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
19	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
20	Multum Information Services, Inc. Expert Review Panel.
21	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
22	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
23	Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
24	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
25	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
26	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
27	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
28	Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
29	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
30	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
31	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
32	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
33	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
34	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
35	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
36	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
37	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
38	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
39	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
40	Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
41	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
42	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
43	Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
44	Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
45	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
46	Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
47	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
48	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
49	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
50	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
51	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
52	Cerner Multum, Inc. "Australian Product Information.".
53	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
54	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
55	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
56	Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.